The role of CA125 in clinical practice

Journal of Clinical Pathology

Volumn 58, Issue 3, 2005, Pages 308-312

  Moss, E L ^a   Hollingworth, J ^a   Reynolds, T M ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BENIGN TUMOR; CANCER SCREENING; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; OVARY CANCER; OVARY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; VALIDATION PROCESS; AGED; EPIDEMIOLOGY; GENERAL HOSPITAL; GENERAL PRACTICE; HOSPITAL LABORATORY; LABORATORY DIAGNOSIS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PREDICTION AND FORECASTING; PUBLIC HOSPITAL; STATISTICS; UNITED KINGDOM; UNNECESSARY PROCEDURE; UTILIZATION REVIEW;

ADULT; AGED; CA-125 ANTIGEN; ENGLAND; EPIDEMIOLOGIC METHODS; FALSE POSITIVE REACTIONS; FAMILY PRACTICE; FEMALE; HOSPITALS, DISTRICT; HOSPITALS, GENERAL; HUMANS; LABORATORIES, HOSPITAL; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; UNNECESSARY PROCEDURES; UTILIZATION REVIEW;

EID: 15044354616     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.018077     Document Type: Article

References (27)

1. Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
2. Tingulstad S, Hagen B, Skieldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31.
3. Ozguroglu M, Turna H, Demir G, et al. Usefulness of the epithelial tumour marker CA125 in non-Hodgkin's lymphoma. Am J Clin Oncol 1999;22:615-18.
4. Levine CD, Patel UJ, Ghanekar D, et al. Benign extraovarian mimics of ovarian cancer. Distinction with imaging studies. Clin Imaging 1997;21:350-8.
5. Meden H, Fattahi-Meibodi A. CA125 in benign gynaecological conditions. Int J Biol Markers 1998;13:231-7.
6. Gaspar MJ, Diez H, Rodriguez A, et al. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. Anticancer Res 2003;23:3427-32.
7. Krishnan STM, Philipose Z, Rayman G. Hypothyroidism mimicking intra-abdominal malignancy. BMJ 2002;325:946-7.
8. Buamah P. Benign conditions associated with raised serum CA125 concentration. J Surg Oncol 2000;75:264-5.
9. Jhang H, Chuang L, Visintainer P, et al. CA125 levels in the preoperative assessment of advanced uterine cancer. Am J Obstet Gynecol 2003;188:1195-7.
10. Predanic M. Differentiating tubal abortion from viable ectopic pregnancy with serum CA125 and beta-human chorionic gonadotropin determinations. Fertil Steril 2000;73:522-5.
11. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150-4.
12. Yilmaz A, Ece F, Bayramgurler B, et al. The value of CA125 in the evaluation of tuberculosis activity. Respir Med 2001;95:666-9.
13. Petaja J, Pitkanen S, Vettenranta K, et al. Serum tumor marker CA125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res 2000;6:531-5.
14. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gyecol Oncol 2002;87:77-83.
15. Alcazar JL, Errasti, Zornoza A, et al. Transvaginal color Doppler ultrasonography and CA125 in suspicious adnexal masses. Int J Gynaecol Obstet 1999;66:255-61.
16. Troíano RN, Quedens-Case C, Taylor KI. Correlation of findings on transvoginal sonography with serum CA125 levels. AJR Am J Roentgenol 1997;168:1587-90.
17. Rustin G. The clinical value of tumour markers in the management of ovarian cancer. Ann Clin Biochem 1996;33:284-9.
18. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73:56-61.
19. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays far discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59:111-16.
20. Schutter EM, Davelaor EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (C125, CA15-3, and CA72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187:385-92.
21. Kerbrat P, Lhomme C, Fervers B, et al. Standards, options and recommendations: ovarian cancer. Electronic Journal of Oncology 2001;1:32-42.
22. Menon U, Jacobs IL. Ovarian cancer screening in the general population. Ultrasound Obstet Gynecol 2000;15:350-3.
23. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA125 elevation in malignant and non-malignant diseases. Gynecol Oncol 2002;85:175-8.
24. Eltabbakh GH, Belinson JL, Kennedy AW, et al. Serum CA125 measurements >65 U/mL. Clinical value. J Reprod Med 1997;42:617-24.
25. Kammerer-Doak DN, Magrina JF, Nemiro JS, et al. Benign gynaecologic conditions associated with a CA-125 level >1,000 U/mL. A case report. J Reprod Med 1996;41:179-82.
26. Daoud E, Bodor G. CA-125 concentrations in malignant and non-malignant disease. Clin Chem 1991;37:1968-74.
27. Duffy MJ, McGing P, McSweeney J. Guidelines for the use of tumour markers. Association of Clinical Biochemists in Ireland, 2nd ed. September, 2000.